Torasemide

Torasemide
Clinical data
Trade names	Demadex ,Tortas
AHFS/Drugs.com	International Drug Names
MedlinePlus	a601212
Routes of; administration	Oral, IV
ATC code	C03CA04 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	80-90%
Protein binding	Highly bound (>99%).
Metabolism	Hepatic (80%)
Elimination half-life	3.5 hours; Cirrhosis: 7-8 hours
Identifiers
	IUPAC name N-[(isopropylamino)carbonyl]-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide;
CAS Number	56211-40-6 ;
PubChem CID	41781;
IUPHAR/BPS	7312;
DrugBank	DB00214 ;
ChemSpider	38123 ;
UNII	W31X2H97FB;
KEGG	D00382 ;
ChEBI	CHEBI:9637 ;
ChEMBL	ChEMBL1148 ;
CompTox Dashboard (EPA)	DTXSID2023690 ;
ECHA InfoCard	100.164.924
Chemical and physical data
Formula	C16H20N4O3S
Molar mass	348.421 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc2cc(C)ccc2;
	InChI InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21) ; Key:NGBFQHCMQULJNZ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Torasemide (rINN) or torsemide (USAN) is a pyridine-sulfonyl urea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. It is marketed under the brand names Demadex, Diuver, and Examide.

Compared with other loop diuretics, torasemide has a more prolonged diuretic effect than equipotent doses of furosemide and relatively decreased potassium loss. No evidence of torasemide-induced ototoxicity has been demonstrated in humans.^[1]

Recent publications suggest improved outcomes when used for heart failure compared with furosemide.^[2]^[3]^[4]

References

^ Dunn CJ, Fitton A, Brogden RN (January 1995). "Torasemide. An update of its pharmacological properties and therapeutic efficacy". Drugs. 49 (1): 121–42. doi:10.2165/00003495-199549010-00009. PMID 7705212.
^ Roush GC, Kaur R, Ernst ME (2014). "Diuretics: a review and update". J. Cardiovasc. Pharmacol. Ther. 19 (1): 5–13. doi:10.1177/1074248413497257. PMID 24243991.
^ Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM (2015). "A reappraisal of loop diuretic choice in heart failure patients". Am. Heart J. 169 (3): 323–33. doi:10.1016/j.ahj.2014.12.009. PMC 4346710. PMID 25728721.
^ Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM (2016). "Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)". Am. J. Cardiol. 117 (3): 404–11. doi:10.1016/j.amjcard.2015.10.059. PMC 4718787. PMID 26704029.

External links

Medlineplus drug information: Torsemide (Systemic) – information from USP DI Advice for the Patient

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[1] Dunn CJ, Fitton A, Brogden RN (January 1995). "Torasemide. An update of its pharmacological properties and therapeutic efficacy". Drugs. 49 (1): 121–42. doi:10.2165/00003495-199549010-00009. PMID 7705212.

[2] Roush GC, Kaur R, Ernst ME (2014). "Diuretics: a review and update". J. Cardiovasc. Pharmacol. Ther. 19 (1): 5–13. doi:10.1177/1074248413497257. PMID 24243991.

[3] Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM (2015). "A reappraisal of loop diuretic choice in heart failure patients". Am. Heart J. 169 (3): 323–33. doi:10.1016/j.ahj.2014.12.009. PMC 4346710. PMID 25728721.

[4] Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM (2016). "Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)". Am. J. Cardiol. 117 (3): 404–11. doi:10.1016/j.amjcard.2015.10.059. PMC 4718787. PMID 26704029.

[1]

[2]

[3]

[4]